Company Description
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 16, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 225 |
| CEO | Dr. Pascal Touchon D.V.M. |
Contact Details
Address: 2380 Conejo Spectrum St, Suite 200 Thousand Oaks, California 91320 United States | |
| Phone | 805-623-4244 |
| Website | atarabio.com |
Stock Details
| Ticker Symbol | ATRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604464 |
| CUSIP Number | 046513107 |
| ISIN Number | US0465131078 |
| Employer ID | 46-0920988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pascal Touchon D.V.M. | President, Chief Executive Officer and Director |
| K. Amar Murugan | Executive Vice President and Chief Legal Officer |
| Eric Hyllengren | Executive Vice President and Chief Financial Officer |
| Dr. Anhco Nguyen Ph.D. | Executive Vice President and Chief Scientific and Technical Officer |
| Alex Chapman | Vice President of Corporate Communications and Investor Relations |
| Jill Henrich | Executive Vice President and Global Head of Regulatory Affairs and Quality |
| Dan Maziasz | Executive Vice President and Chief Business Officer |
| Rajani Dinavahi M.D. | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 4, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |